AI-Driven Hospital Readmission Predictor Market Report 2026

The artificial intelligence (AI)-driven hospital readmission predictor market size has grown exponentially in recent years. It will grow from $1.92 billion in 2025 to $2.42 billion in 2026 at a compound annual growth rate (CAGR) of 26.2%. The growth in the historic period can be attributed to increasing adoption of AI in healthcare, growing demand to reduce hospital readmissions, rising availability of electronic health records, expansion of predictive analytics usage, and increasing focus on patient outcomes.

The artificial intelligence (AI)-driven hospital readmission predictor market size is expected to see exponential growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 25.9%. The growth in the forecast period can be attributed to rising investments in healthcare IT infrastructure, growing integration of clinical decision support systems, increasing adoption of cloud-based analytics platforms, expansion of remote patient monitoring tools, and growing emphasis on value-based care models. Major trends in the forecast period include technology advancements in machine learning models, innovations in real-time patient monitoring, research and developments in natural language processing, the development of explainable AI for healthcare, and advancements in interoperable healthcare IT systems.

The increasing prevalence of chronic diseases is expected to propel the growth of the artificial intelligence (AI)-driven hospital readmission predictor market going forward. Chronic diseases are long-lasting health conditions that usually progress slowly over time, such as diabetes, heart disease, and arthritis, and often require ongoing medical attention and lifestyle management to control symptoms and prevent complications. Chronic diseases are increasing largely due to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which raise the risk of conditions such as diabetes, heart disease, and obesity. Artificial intelligence (AI)-driven hospital readmission predictors aid in chronic disease management by analyzing patient data to identify those at high risk of readmission. They improve patient outcomes by enabling proactive interventions, personalized care plans, and timely follow-up to prevent complications and reduce hospital stays. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the artificial intelligence (AI)-driven hospital readmission predictor market.

Leading companies operating in the artificial intelligence (AI)-driven hospital readmission predictor market are focusing on developing advanced solutions, such as advanced predictive modeling, to identify high-risk patients, enable proactive interventions, and optimize post-discharge care. Advanced predictive modeling refers to the use of sophisticated statistical algorithms and machine learning techniques on historical and real-time data to uncover complex patterns and generate highly accurate forecasts of future outcomes. For instance, in July 2025, Innovaccer Inc., a US-based healthcare AI company, launched its AI-Powered Readmissions Management Solution, which integrates advanced predictive modeling to flag avoidable readmissions across Medicare, Medicaid, and uninsured populations. The platform also provides unified 360-degree patient views, agentic AI tools such as Care Management Copilot and Pre-Call Coordinator Agent for workflow automation, and benchmark intelligence for proactive intervention planning. This solution helps healthcare providers reduce readmission rates, improve resource allocation, and enhance overall patient outcomes.

In July 2024, SAIGroup, a US-based enterprise AI investment firm specializing in healthcare and enterprise intelligence solutions, acquired GetWellNetwork Inc. for an undisclosed amount. Through this acquisition, SAIGroup aims to integrate advanced predictive and generative AI into GetWell’s patient engagement platform, enhancing predictive insights into patient behaviors and clinical outcomes to reduce hospital readmissions, optimize care transitions, and improve overall hospital operational efficiency. GetWellNetwork Inc. is a US-based healthcare technology company specializing in AI-driven hospital readmission prediction solutions.

Major companies operating in the artificial intelligence (AI)-driven hospital readmission predictor market are Oracle Corporation, Siemens Healthineers AG, Cognizant Technology Solutions Corp., Epic Systems Corporation, SAS Institute Inc., Veradigm Inc., Merative LLP, Health Catalyst Inc., Lumeris Inc., Innovaccer Inc., Optum Inc., H2O.ai Inc., Healthfirst Inc., Qventus Inc., Lightbeam Health Solutions Inc., HealthEC LLC, Collective Medical Technologies Inc., CarePredict Inc., HBI Solutions Inc., CloudMedx.

North America was the largest region in the artificial intelligence (AI)-driven hospital readmission predictor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven hospital readmission predictor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-driven hospital readmission predictor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have affected the ai-driven hospital readmission predictor market by increasing the cost of imported hardware, servers, and sensors used in predictive systems. the impact is most notable in regions reliant on imported technology such as north america and europe, particularly for hardware components. software and cloud-based solutions face relatively lower tariff pressures, allowing some segments to benefit from localized development and deployment. overall, tariffs have slightly increased operational costs but have also encouraged manufacturers to invest in regional production and supply chain diversification.

An artificial intelligence (AI)-driven hospital readmission predictor is a digital healthcare solution that utilizes AI and machine learning models to estimate the likelihood of a patient being readmitted after discharge. It analyzes comprehensive clinical, behavioral, and historical health data to identify patterns associated with elevated readmission risk. Healthcare providers and care teams leverage these insights to enhance care planning, reduce avoidable readmissions, and improve patient outcomes.

The main components of AI-driven hospital readmission predictor solutions are software, hardware, and services. Software consists of predictive analytics platforms that evaluate clinical, operational, and patient data to identify high-risk individuals and support proactive care strategies. These solutions are deployed through on-premises and cloud models and are applied in patient risk assessment, care management, clinical decision support, population health management, and more, among users such as hospitals, clinics, ambulatory surgical centers, and others.

The artificial intelligence (AI)-driven hospital readmission predictor market consists of revenues earned by entities by providing services such as patient readmission risk assessment, predictive analytics and modeling, clinical decision support, and care pathway optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-driven hospital readmission predictor market also includes sales of AI-based predictive analytics software, hospital readmission risk prediction platforms, machine learning models and algorithms, and dashboard and reporting tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.